NRBO: NeuroBo Pharmaceuticals Inc. Stocks News on November 22, 2024

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

NRBO

PR Newswire

4 days ago

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

Life Sciences Investor Forum: Presentations Now Available for Online Viewing

NRBO

GlobeNewswire

7 days ago

Life Sciences Investor Forum: Presentations Now Available for Online Viewing

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

NRBO

PR Newswire

9 days ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

NRBO

Zacks Small Cap Research

9 days ago

NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024...

NRBO

Zacks Small Cap Research

9 days ago

NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024

Life Sciences Investor Forum Agenda Announced for November 14th

NRBO

GlobeNewswire

10 days ago

Life Sciences Investor Forum Agenda Announced for November 14th

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

NRBO

PR Newswire

15 days ago

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NRBO

PR Newswire

18 days ago

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NRBO

Zacks Small Cap Research

2 months ago

NRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25…

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

NRBO

PR Newswire

2 months ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

NRBO

Simply Wall St.

2 months ago

We're A Little Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Rate

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NRBO

PR Newswire

2 months ago

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

NRBO

PR Newswire

3 months ago

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

NRBO

Zacks Small Cap Research

3 months ago

NRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24…

NRBO

MT Newswires

3 months ago

NeuroBo Pharmaceuticals Shares Rise After Reporting Q2 Results

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

NRBO

PR Newswire

3 months ago

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

NeuroBo concludes subject enrolment in SAD portion of obesity treatment trial

NRBO

Clinical Trials Arena

3 months ago

NeuroBo concludes subject enrolment in SAD portion of obesity treatment trial

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NRBO

PR Newswire

3 months ago

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

NRBO

PR Newswire

4 months ago

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

NRBO

PR Newswire

4 months ago

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now

NRBO

GlobeNewswire

4 months ago

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now

NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

NRBO

PR Newswire

4 months ago

NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

NRBO

Zacks Small Cap Research

5 months ago

NRBO: DA-1726 Shows Superiority to Survodutide in Pre-Clinical Models…

NeuroBo doses first subject in Part 2 of Phase I obesity treatment trial

NRBO

Clinical Trials Arena

5 months ago

NeuroBo doses first subject in Part 2 of Phase I obesity treatment trial

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NRBO

PR Newswire

5 months ago

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NRBO

MT Newswires

5 months ago

NeuroBo Pharmaceuticals Raises $20 Million from Share Placement

NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NRBO

PR Newswire

5 months ago

NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NRBO

MT Newswires

5 months ago

NeuroBo Pharmaceuticals Announces Private Placement, Registered Direct Offering

NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NRBO

PR Newswire

5 months ago

NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

NRBO

PR Newswire

5 months ago

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

Edge Total Intelligence Inc. Updates Status of MCTO

NRBO

Newsfile

5 months ago

Edge Total Intelligence Inc. Updates Status of MCTO

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

NRBO

CNW Group

5 months ago

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY

NRBO

GlobeNewswire

5 months ago

Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY

LED Driver with CAN Bus for Dynamic Automotive Interior RGB Lighting

NRBO

GlobeNewswire

5 months ago

LED Driver with CAN Bus for Dynamic Automotive Interior RGB Lighting

Nokia introduces Network Exposure Platform to expand and simplify network API exposure for service providers

NRBO

GlobeNewswire

5 months ago

Nokia introduces Network Exposure Platform to expand and simplify network API exposure for service providers

The sale of Aspo's subsidiary ESL Shipping's Supramax vessels has been completed on June 11 2024

NRBO

GlobeNewswire

5 months ago

The sale of Aspo's subsidiary ESL Shipping's Supramax vessels has been completed on June 11 2024

HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA

NRBO

CNW Group

5 months ago

HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

NRBO

PR Newswire

5 months ago

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities

NRBO

PR Newswire

5 months ago

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities

NRBO

Business Wire

5 months ago

Form 8.3 - International Distribution Services plc

NRBO

Business Wire

5 months ago

Form 8.3 - Darktrace plc

US Supreme Court rejects Kroger challenge to Grubhub trademark win

NRBO

Reuters

5 months ago

US Supreme Court rejects Kroger challenge to Grubhub trademark win

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect

NRBO

Investor's Business Daily

5 months ago

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina

NRBO

Business Wire

5 months ago

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina

NRBO

GlobeNewswire

5 months ago

Middlefield Canadian Income PCC: Net Asset Value(s)

NRBO

Business Wire

5 months ago

Form 8.3 - International Paper Company

NRBO

Zacks Small Cap Research

6 months ago

NRBO: Preclinical Data on DA-1241 with Semaglutide to be Presented at EASL Congress 2024

NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

NRBO

PR Newswire

6 months ago

NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

NRBO

PR Newswire

6 months ago

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

NRBO

PR Newswire

7 months ago

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

NRBO

Zacks Small Cap Research

7 months ago

NRBO: First Patient Dosed in Phase 1 Trial of DA-1726 for the Treatment of Obesity…

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NRBO

PR Newswire

7 months ago

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NRBO

PR Newswire

8 months ago

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

NRBO

PR Newswire

8 months ago

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NRBO

PR Newswire

8 months ago

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

NRBO

PR Newswire

9 months ago

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NRBO

PR Newswire

9 months ago

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference

NRBO

PR Newswire

9 months ago

NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

NRBO

PR Newswire

10 months ago

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Clough Global Dividend and Income Fund Section 19(a) Notice

NRBO

ACCESSWIRE

10 months ago

Clough Global Dividend and Income Fund Section 19(a) Notice

SEALSQ SEALCOIN: A Game Changer in Machine-to-Machine Economy

NRBO

GlobeNewswire

10 months ago

SEALSQ SEALCOIN: A Game Changer in Machine-to-Machine Economy

NRBO

Business Wire

10 months ago

Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference

WISeKey Celebrates its 25th Anniversary with a Strategic Shift to Web 3.0, Championing a Neutral, Secure, and Decentralized Internet

NRBO

GlobeNewswire

10 months ago

WISeKey Celebrates its 25th Anniversary with a Strategic Shift to Web 3.0, Championing a Neutral, Secure, and Decentralized Internet

Battery & Precious Metals Virtual Investor Conference Agenda Announced for January 30 - February 1, 2024

NRBO

GlobeNewswire

10 months ago

Battery & Precious Metals Virtual Investor Conference Agenda Announced for January 30 - February 1, 2024

United Security Bancshares (UBFO) Reports Record Net Income for 2023

NRBO

GuruFocus.com

10 months ago

United Security Bancshares (UBFO) Reports Record Net Income for 2023

First US Bancshares, Inc. Reports 25.5% Year-Over-Year Diluted EPS Growth

NRBO

PR Newswire

10 months ago

First US Bancshares, Inc. Reports 25.5% Year-Over-Year Diluted EPS Growth

Chuck Royce's Firm Adjusts Position in Orion Group Holdings Inc

NRBO

GuruFocus.com

10 months ago

Chuck Royce's Firm Adjusts Position in Orion Group Holdings Inc

BM Technologies (BMTX) Champions Campus Excellence and Announces 2023 ACE Award and Partnership Winners

NRBO

ACCESSWIRE

10 months ago

BM Technologies (BMTX) Champions Campus Excellence and Announces 2023 ACE Award and Partnership Winners

Bright Green Corporation announces the agreement to acquire platform technologies and associated intellectual property from C2 Wellness Corp.

NRBO

GlobeNewswire

10 months ago

Bright Green Corporation announces the agreement to acquire platform technologies and associated intellectual property from C2 Wellness Corp.

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer

NRBO

GlobeNewswire

10 months ago

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer

Forbes-Approved: CareCloud is Streamlining Healthcare with Smart Technology for All Practices

NRBO

GlobeNewswire

10 months ago

Forbes-Approved: CareCloud is Streamlining Healthcare with Smart Technology for All Practices

4 Silver Mining Stocks to Watch Amid Industry Challenges

NRBO

Zacks

10 months ago

4 Silver Mining Stocks to Watch Amid Industry Challenges

CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics

NRBO

GlobeNewswire

10 months ago

CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics

NRBO

Motley Fool

10 months ago

Why Coherus Biosciences Popped Today

Here's Why We're A Bit Worried About FTC Solar's (NASDAQ:FTCI) Cash Burn Situation

NRBO

Simply Wall St.

10 months ago

Here's Why We're A Bit Worried About FTC Solar's (NASDAQ:FTCI) Cash Burn Situation

Shareholders in Marchex (NASDAQ:MCHX) are in the red if they invested five years ago

NRBO

Simply Wall St.

10 months ago

Shareholders in Marchex (NASDAQ:MCHX) are in the red if they invested five years ago

NRBO

Business Wire

10 months ago

Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series

NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NRBO

PR Newswire

10 months ago

NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

CENTOGENE Announces Preliminary Full Year 2023 Revenue

NRBO

GlobeNewswire

10 months ago

CENTOGENE Announces Preliminary Full Year 2023 Revenue

NRBO

Zacks Small Cap Research

10 months ago

NRBO: Initiating Coverage of NeuroBo Pharmaceuticals, Inc.; Targeting the $30 Billion+ Obesity Market…

Investing in Research Solutions (NASDAQ:RSSS) a year ago would have delivered you a 28% gain

NRBO

Simply Wall St.

10 months ago

Investing in Research Solutions (NASDAQ:RSSS) a year ago would have delivered you a 28% gain

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

NRBO

GlobeNewswire

10 months ago

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

NRBO

GlobeNewswire

10 months ago

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

NRBO

Business Wire

10 months ago

Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis

Avino’s Q4 and Full Year 2023 Production Results

NRBO

ACCESSWIRE

10 months ago

Avino’s Q4 and Full Year 2023 Production Results

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

NRBO

PR Newswire

10 months ago

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

SPI Energy's Solar4America presents American-Made Solar Modules & Announces American Solar Cell Production at ISNA/ESNA in San Diego

NRBO

ACCESSWIRE

10 months ago

SPI Energy's Solar4America presents American-Made Solar Modules & Announces American Solar Cell Production at ISNA/ESNA in San Diego

Is BTCS Inc. (BTCS) Outperforming Other Finance Stocks This Year?

NRBO

Zacks

10 months ago

Is BTCS Inc. (BTCS) Outperforming Other Finance Stocks This Year?

Here's Why We Think First US Bancshares (NASDAQ:FUSB) Is Well Worth Watching

NRBO

Simply Wall St.

10 months ago

Here's Why We Think First US Bancshares (NASDAQ:FUSB) Is Well Worth Watching

Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care (SOC) in Genetic Disease Testing

NRBO

GlobeNewswire

10 months ago

Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care (SOC) in Genetic Disease Testing

NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement

NRBO

PR Newswire

10 months ago

NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement

Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

NRBO

Newsfile

10 months ago

Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Concord Medical Announces Listing of Its Subsidiary on The Stock Exchange of Hong Kong Limited

NRBO

PR Newswire

10 months ago

Concord Medical Announces Listing of Its Subsidiary on The Stock Exchange of Hong Kong Limited

Avino Signs Community Agreements for La Preciosa

NRBO

ACCESSWIRE

10 months ago

Avino Signs Community Agreements for La Preciosa

Spero Therapeutics Provides Corporate Update and 2024 Outlook

NRBO

GlobeNewswire

a year ago

Spero Therapeutics Provides Corporate Update and 2024 Outlook

NRBO

Business Wire

a year ago

Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Quince Therapeutics to Participate at Investor Events in January 2024

NRBO

Business Wire

a year ago

Quince Therapeutics to Participate at Investor Events in January 2024

Assembly Biosciences Provides Anticipated Development Milestones for 2024

NRBO

GlobeNewswire

a year ago

Assembly Biosciences Provides Anticipated Development Milestones for 2024

authID Continues Growth Momentum with Strong Q4 Sales

NRBO

GlobeNewswire

a year ago

authID Continues Growth Momentum with Strong Q4 Sales

Comstock Inc. Publishes its 4Q23 Stakeholder Perception Analysis Report

NRBO

GlobeNewswire

a year ago

Latest NeuroBo Pharmaceuticals Inc. (NRBO) News on November 22, 2024

Share on Social Networks: